Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Table 3 Relative size of anti-EGFR mAb efficacy for PIK3CA mutant tumors compared to PIK3CA wild-type tumors. Results stratified by anti-EGFR drug and line of therapy

Subgroup	PFS			P value for interaction^*	OS			P value for interaction^*
	N Trials	Interaction Hazard Ratio (95% CI)	Interaction P value	P value for interaction^*	N Trials	Interaction Hazard Ratio (95% CI)	Interaction P value	P value for interaction^*
Anti-EGFR drug				0.53				0.70
Cetuximab	2	1.26 (0.77, 2.04)	0.36		2	1.00 (0.59, 1.70)	0.99
Panitumumab	2	1.71 (0.75, 3.92)	0.21		1	1.21 (0.53, 2.77)	0.66
Line of therapy				0.59				0.87
First	1	1.50 (0.86, 2.60)	0.15		1	1.10 (0.58, 2.06)	0.77
≥ Second	3	1.19 (0.62, 2.26)	0.60		2	1.02 (0.55, 1.91)	0.95

^*Test comparing the HRs between trial subgroups (cetuximab; panitumumab; line of therapy)

ISSN: 1471-2407